Weiss Asset Management’s Theravance Biopharma TBPH Stock Holding History

Weiss Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$127M	Hold	7,457,060	–	–	1.33%	12
2026 Q1	$121M	Hold	7,457,060	–	–	2.04%	8
2025 Q4	$140M	Hold	7,457,060	–	–	1.84%	8
2025 Q3	$109M	Hold	7,457,060	–	–	1.26%	16
2025 Q2	$82.3M	Hold	7,457,060	–	–	0.94%	13
2025 Q1	$66.6M	Hold	7,457,060	–	–	1.33%	14
2024 Q4	$70.2M	Hold	7,457,060	–	–	1.31%	14
2024 Q3	$60.1M	Hold	7,457,060	–	–	1.31%	12
2024 Q2	$63.2M	Hold	7,457,060	–	–	2.39%	5
2024 Q1	$66.9M	Hold	7,457,060	–	–	2.3%	7
2023 Q4	$83.8M	Hold	7,457,060	–	–	4%	3
2023 Q3	$64.4M	Hold	7,457,060	–	–	3.81%	5
2023 Q2	$77.2M	Hold	7,457,060	–	–	5.92%	3
2023 Q1	$80.9M	Hold	7,457,060	–	–	5.18%	2
2022 Q4	$83.7M	Hold	7,457,060	–	–	3.41%	2
2022 Q3	$75.6M	Buy	7,457,060 +1,219,622	+20%	+$11.4M	1.86%	4
2022 Q2	$56.5M	Buy	6,237,438 +824,951	+15%	+$7.6M	1.38%	11
2022 Q1	$51.7M	Buy	5,412,487 +2,810,709	+108%	+$27.5M	1.07%	13
2021 Q4	$28.8M	Buy	+2,601,778	New	+$22.7M	0.62%	26

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

ICM

Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Weiss Asset Management's TBPH Position: Q2 2026 in Review

Weiss Asset Management held its Theravance Biopharma (TBPH) position steady in Q2 2026 at 7,457,060 shares worth $127M. The position accounts for 1.33% of the portfolio, ranked #12.

Weiss Asset Management first reported a position in TBPH in Q4 2021 and has held it in 19 quarters since. The position peaked at $140M in Q4 2025. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

Weiss Asset Management held 7,457,060 shares of Theravance Biopharma worth $127M as of Q2 2026.
Weiss Asset Management left its Theravance Biopharma share count unchanged in Q2 2026.
Theravance Biopharma made up 1.33% of Weiss Asset Management's portfolio in Q2 2026, its #12 holding.
Weiss Asset Management first reported a position in Theravance Biopharma in Q4 2021 and has held it in 19 quarters since.
Weiss Asset Management's Theravance Biopharma position peaked at $140M in Q4 2025.
181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Weiss Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.